We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid DNA Sequencing Technology Could Improve Treatment for Fracture-Related Infections

By LabMedica International staff writers
Posted on 12 Jun 2025

Fracture-related infections are a serious complication after broken bone surgeries, potentially arising at any point during treatment. More...

These infections can significantly prolong recovery, impair bone healing, cause permanent disability or even amputation, and often require repeated surgeries, costing the healthcare system billions annually. Despite progress in orthopedic trauma care, treatment for these infections still fails in about 30% of cases. Now, a new multicenter clinical trial is evaluating whether rapid next-generation DNA sequencing can improve patient outcomes and reduce the rate of treatment failure and recurrent infection.

The study, led by researchers at Indiana University School of Medicine (Indianapolis, IN, USA), is being conducted through the Major Extremity Trauma Research Consortium, which comprises over 80 trauma centers across the U.S. and Canada. The research spans 15 clinical sites and will follow 250 patients, aged 18 to 84, over the course of four years. It brings together a multidisciplinary team of experts in trauma, infectious diseases, and molecular diagnostics. Unlike traditional diagnostic methods such as polymerase chain reaction (PCR) and culture tests — which are limited in their ability to detect a broad range of pathogens — next-generation sequencing reads microbial DNA to comprehensively identify bacteria and fungi present in a sample. This technology offers a more detailed and faster analysis of the infectious agents responsible for complications following orthopedic surgery.

Patients enrolled in the trial will receive standard care alongside next-generation sequencing diagnostics provided by industry partner MicroGenDX (Orlando, FL, USA). Hospital-based infectious disease specialists will use these sequencing results to tailor antibiotic treatment plans for each patient. Treatment effectiveness will then be monitored for one year, aligning with standard care protocols. If successful, this study could transform the management of fracture-related infections by enabling earlier, more precise interventions. Improved diagnostics may lead to fewer re-hospitalizations, less need for repeat surgeries or amputations, more survivors, and major cost savings for healthcare systems. Researchers believe next-generation sequencing may give clinicians more information to help them decide what the best course of action is for individual patients.

"We hope to get more information from the next-generation sequencing diagnostics that will uncover pathogens that would have not been identified by our current standard tools," said Roman M. Natoli, MD, PhD, associate professor of orthopedic surgery in the Department of Orthopedic Surgery at IU School of Medicine and principal investigator of the clinical trial. "This trial will allow us to choose more appropriate antibiotic treatment via next-generation sequencing results and ultimately, if we're correct, reduce the rate of failure for treating patients that have infections after fractures. We hope to not only reduce the failure rate in fracture-related infections but also bring wounded warriors and civilians to more optimal function, where they can return to active duty, work and life."

Related Links:
Indiana University School of Medicine
MicroGenDX


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.